One-year mortality and varying ascertainment windows for a Medicare claims-based proxy for frailty in women with stage I-III breast cancer. Issue 28 (1st October 2022)

• Record Type: Journal Article
• Authors: Duchesneau, Emilie Danielle; Sturmer, Til; Kim, Dae Hyun; Jonsson Funk, Michele; Poole, Charles; Kinlaw, Alan C; Faurot, Keturah R; Her, Qoua L; Wang, Tiansheng; Lund, Jennifer Leigh
• Is Part Of: Journal of clinical oncology. Volume 40:Issue 28(2022)Supplement
• Page Start: 396
• Page End: 396
• Publication Date: 2022-10-01
• Subjects: 261-492-199-2823-9141 -- 261-492-574 -- 329-334-533 -- 281-318-2407 -- 283-217; 19 -- 9 -- 2 -- 2 -- 2; Oncology -- Periodicals; Cancer -- Periodicals; Oncology; Medical Oncology; Cancérologie -- Périodiques; Cancer -- Périodiques; Cancérologie; Cancer; Oncology; Oncologia; Càncer; Periodicals; 616.994
• DOI: 10.1200/JCO.2022.40.28_suppl.396
• Languages: English
• ISSNs: 0732-183X

Abstract

Abstract : 396 Background: Frail cancer patients are more likely to die or experience treatment toxicity than non-frail patients. The Faurot frailty index (FFI) is a validated Medicare claims-based proxy that predicts frailty in individuals. Frailty is dynamic and can change over time. We assessed the distribution of the FFI and associations with 1-year mortality using varying durations of frailty ascertainment windows in breast cancer patients. Methods: We identified women (66+ yrs) with stage I-III breast cancer in the SEER-Medicare database who had ≥1 year of continuous enrollment in Medicare Parts A and B prior to diagnosis. The FFI-predicted probability of frailty was assessed using demographic and diagnostic and procedural billing information during varying pre-diagnosis ascertainment windows: 3, 6, 8, or 12 months or using all available pre-diagnosis claims. We described the distributions of the claims-based frailty measures using each of the five ascertainment windows and reported 1-year mortality for individuals with high (≥0.20), medium (0.05 - < 0.20), or low (< 0.05) claims-based frailty using Kaplan-Meier analysis. Follow-up began on the date of cancer diagnosis. Results: We identified 235, 145 women with breast cancer. Using a 3-month ascertainment window, 76%, 20%, and 4% were classified as having low, medium, and high claims-based frailty. Although the distributions of claims-based frailty were similar using 3, 6, 8, and 12-month frailty ascertainment windows, the use of all available lookback led a wider interquartile range (IQR) for claims-based frailty (Table). Overall, 4% of women died within 1 year of diagnosis. Higher claims-based frailty was strongly associated with increased 1-year mortality risk, using each ascertainment window. Mortality associations were strongest with a 3-month ascertainment window: risk difference (RD) high vs. low frailty 20% (95% CI, 19-20%). Associations were weakest with an all available lookback window: RD high vs. low frailty 11% (95% CI, 11-12%). Conclusions: Varying frailty ascertainment window durations did not lead to substantial differences in the distribution of the FFI in women with stage I-III breast cancer. Associations between the FFI and 1-year mortality monotonically decreased with increasing ascertainment window durations. This may be due to claims in the distant past having less etiological relevance for predicting mortality during the year following cancer diagnosis.Frailty ascertainment window (months) Median FFI (IQR) 1-year mortality risk (%) Low frailty 1-year mortality risk (%) Medium frailty 1-year mortality risk (%) High frailty RD (95% CI) Medium vs. low RD (95% CI) High vs. low 3 0.03 (0.02-0.05) 2 8 22 6 (6-6) 20 (19-20) 6 0.03 (0.02-0.05) 2 7 19 5 (5-6) 18 (17-18) 8 0.03 (0.02-0.05) 2 7 19 5 (5-5) 17 (16-18) 12 0.03 (0.02-0.06) 2 7 18 5 (4-5) 16 (15-17) All lookback 0.03 (0.02-0.10) 2 5 13 3 (3-3) 11 (11-12)